Community Practice Connections: Show Me the Data: The Experts Weigh - In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma
WebcastFaculty
OVERVIEW
Community Practice Connections: Show Me the Data: The Experts Weigh - In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma is organized by Physicians Education Resource, LLC (PER) and will be held during Aug 31, 2017 - Aug 31, 2018.
The target audience for this medical event is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with renal cell carcinoma are invited to participate. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits
Conference Overview :
This conference features case-based discussions about standard and emerging therapies for renal cell carcinoma (RCC). Interactive clinical vignettes are followed by brief video interviews with leading experts and short summaries of related clinical data. The vignettes and video interviews broach a variety of clinical scenarios at key junctures in care, with the understanding that real-world scenarios cannot always be bucketed neatly into simple “lines of therapy.” The format of this activity enables participants to reflect on how they arrive at the decisions they make, how their decisions compare with those of the faculty, whether they have a deep understanding of landmark trial results, and how to better contextualize evidence to optimize decision making at key decision points along the RCC treatment continuum.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Substantiate your treatment decisions in the management of advanced RCC at key decision points along the disease continuum based on the most relevant clinical trial evidence
• Integrate knowledge of single-agent and combination strategies in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs switching decisions in the care of patients with advanced RCC
• Manage treatment-related toxicities and practically apply knowledge of adverse events as a component of monitoring and therapeutic decision making in RCC treatment settings
• Assess recent clinical trial results, key ongoing trials that are highly anticipated in the field, and how emerging strategies may further impact the RCC treatment landscape
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with renal cell carcinoma are invited to participate. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits
Conference Overview :
This conference features case-based discussions about standard and emerging therapies for renal cell carcinoma (RCC). Interactive clinical vignettes are followed by brief video interviews with leading experts and short summaries of related clinical data. The vignettes and video interviews broach a variety of clinical scenarios at key junctures in care, with the understanding that real-world scenarios cannot always be bucketed neatly into simple “lines of therapy.” The format of this activity enables participants to reflect on how they arrive at the decisions they make, how their decisions compare with those of the faculty, whether they have a deep understanding of landmark trial results, and how to better contextualize evidence to optimize decision making at key decision points along the RCC treatment continuum.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Substantiate your treatment decisions in the management of advanced RCC at key decision points along the disease continuum based on the most relevant clinical trial evidence
• Integrate knowledge of single-agent and combination strategies in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs switching decisions in the care of patients with advanced RCC
• Manage treatment-related toxicities and practically apply knowledge of adverse events as a component of monitoring and therapeutic decision making in RCC treatment settings
• Assess recent clinical trial results, key ongoing trials that are highly anticipated in the field, and how emerging strategies may further impact the RCC treatment landscape
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links